Newly acquired infection with multidrug-resistant HIV-1 in a patient adherent to preexposure prophylaxis

Journal of Acquired Immune Deficiency Syndromes

Volumn 76, Issue 4, 2017, Pages e104-e106

  Markowitz, Martin ^a   Grossman, Howard ^b   Anderson, Peter L ^c   Grant, Robert ^d   Gandhi, Monica ^d   Horng, Howard ^d   Mohri, Hiroshi ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b DEPARTMENT OF COLORECTAL SURGERY   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; COBICISTAT PLUS DARUNAVIR; DOLUTEGRAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; TENOFOVIR; VIRUS DNA; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ADULT; ANAL INTERCOURSE; ANTIRETROVIRAL THERAPY; ANTIVIRAL RESISTANCE; CASE REPORT; CD4+ T LYMPHOCYTE; CLINICAL ARTICLE; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; CONTROLLED STUDY; DNA EXTRACTION; DNA SEQUENCE; DRUG HAIR LEVEL; GONORRHEA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INSERTIVE CONDOMLESS ANAL INTERCOURSE; INSERTIVE INTERCOURSE; LETTER; MALE; MEDICATION COMPLIANCE; MEN WHO HAVE SEX WITH MEN; MULTIDRUG RESISTANCE; PATIENT COMPLIANCE; PHARMACOGENETICS; POLYMERASE CHAIN REACTION; PRE-EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RECEPTIVE CONDOMLESS ANAL INTERCOURSE; RECEPTIVE INTERCOURSE; SELF REPORT; SEROCONVERSION; SEXUALITY; TREATMENT DURATION; URETHRITIS; VIRUS LOAD; DRUG EFFECT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MUTATION; STATISTICS AND NUMERICAL DATA; TRANSMISSION; VIROLOGY;

ADULT; ANTI-HIV AGENTS; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; MALE; MEDICATION ADHERENCE; MUTATION; PRE-EXPOSURE PROPHYLAXIS; SEXUAL PARTNERS;

EID: 85042113519     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000001534     Document Type: Letter

References (23)

1. Grant RM, Anderson PL, McMahan V, et al. Uptake of pre-exposure prophylaxis, sexual practices, and HIV incidence in men and transgender women who have sex with men: a cohort study. Lancet Infect Dis. 2014; 14: 820-829.
2. Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010; 363:2587-2599.
3. Liu AY, Cohen SE, Vittinghoff E, et al. Preexposure prophylaxis for HIV infection integrated with municipal- and community-based sexual health services. JAMA Intern Med. 2016; 176:75-84.
4. McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016; 387:53-60.
5. Baeten JM, Donnell D, Ndase P, et al. Anti-retroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012; 367:399-410.
6. Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012; 367:423-434.
7. Fonner VA, Dalglish SL, Kennedy CE, et al. Effectiveness and safety of oral HIV preexpo-sure prophylaxis for all populations. AIDS. 2016; 30:1973-1983.
8. Anderson PL, Glidden DV, Liu A, et al. Emtricitabine-tenofovir concentrations and pre-exposure prophylaxis efficacy in men who have sex with men. Sci Transl Med. 2012; 4:151ra125.
9. Donnell D, Baeten JM, Bumpus NN, et al. HIV protective efficacy and correlates of tenofovir blood concentrations in a clinical trial of PrEP for HIV prevention. J Acquir Immune Defic Syndr. 2014; 66:340-348.
10. Dai JY, Hendrix CW, Richardson BA, et al. Pharmacological measures of treatment adherence and risk of HIV infection in the VOICE study. J Infect Dis. 2016; 213:335-342.
11. Castillo-Mancilla JR, Zheng JH, Rower JE, et al. Tenofovir, emtricitabine, and tenofovir diphosphate in dried blood spots for determining recent and cumulative drug exposure. AIDS Res Hum Retroviruses. 2013; 29:384-390.
12. Gandhi M, Glidden DV, Mayer K, et al. Association of age, baseline kidney function, and medication exposure with declines in creatinine clearance on pre-exposure prophylaxis: an observational cohort study. Lancet HIV. 2016; 3:e521-e528.
13. Liu AY, Yang Q, Huang Y, et al. Strong relationship between oral dose and tenofovir hair levels in a randomized trial: hair as a potential adherence measure for pre-exposure prophylaxis (PrEP). PLoS One. 2014; 9:e83736.
14. Markowitz M, Evering TH, Garmon D, et al. A randomized open-label study of 3- versus 5- drug combination antiretroviral therapy in newly HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2014; 66:140-147.
15. Rhee SY, Gonzales MJ, Kantor R, et al. Human immunodeficiency virus reverse tran-scriptase and protease sequence database. Nucleic Acids Res. 2003; 31:298-303.
16. Knox DC, Anderson PL, Harrigan PR, et al. Multidrug-resistant HIV-1 infection despite preexposure prophylaxis. N Engl J Med. 2017; 376:501-502.
17. Patel P, Borkowf CB, Brooks JT, et al. Estimating per-act HIV transmission risk: a systematic review. AIDS. 2014; 28:1509-1519.
18. de Souza MS, Pinyakorn S, Akapirat S, et al. Initiation of antiretroviral therapy during acute HIV-1 infection leads to a high rate of non-reactive HIV serology. Clin Infect Dis. 2016; 63:555-561.
19. Prada N, Davis B, Jean-Pierre P, et al. Drug-susceptible HIV-1 infection despite intermittent fixed-dose combination tenofo-vir/emtricitabine as prophylaxis is associated with low-level viremia, delayed seroconversion, and an attenuated clinical course. J Acquir Immune Defic Syndr. 2008; 49:117-122.
20. Branson BM, Owen SM, Wesolowski LG, et al. Centers for Disease Control and Prevention and Association of Public Health Laboratories: Laboratory Testing for the Diagnosis of HIV Infection: Updated Recommendations; 2014. Available at: http://stacks.cdc.gov/view/cdc/23447. Accessed September 19, 2017.
21. Hoornenborg E, de Bree GJ Acute Infection With a Wild-Type HIV-1 Virus in PrEP User With High TDF Levels. Conference on Retro-viruses and Opportunistic Infections; February 13-16, 2017. Seattle, WA; 2017.
22. Castor D, Low A, Evering T, et al. Transmitted drug resistance and phylogenetic relationships among acute and early HIV-1-infected individuals in New York City. J Acquir Immune Defic Syndr. 2012; 61:1-8.
23. Shet A, Berry L, Mohri H, et al. Tracking the prevalence of transmitted antiretroviral drug-resistant HIV-1: a decade of experience. J Acquir Immune Defic Syndr. 2006; 41: 439-446.